Sign in

    Marla Marin

    Research Analyst at Bluegrass Capital Partners

    No verifiable public, professional profile or credible performance metrics exist for Marla Marin as an analyst at Bluegrass Capital Partners. No evidence could be located regarding their job title, coverage universe, analyst rankings, career path, or financial services credentials. There are no available records indicating coverage of specific companies, track record on any analyst-ranking platforms, regulatory licenses, or prior industry experience. As a result, no comprehensive professional profile can be produced for Marla Marin at Bluegrass Capital Partners based on publicly available sources.

    Marla Marin's questions to AETHLON MEDICAL (AEMD) leadership

    Marla Marin's questions to AETHLON MEDICAL (AEMD) leadership • Q1 2026

    Question

    Marla Marin of Zacks Investment Research inquired about the Australian trial's primary safety endpoint, whether the high efficacy seen in preclinical data (98.5% EV removal) is a realistic expectation for the clinical study, and the strategic versus financial rationale for discontinuing the planned trial in India.

    Answer

    Chief Medical Officer Dr. Steven LaRosa confirmed the trial is on track to meet its primary safety endpoint after the first cohort passed review by the independent Data Safety Monitoring Board. He also clarified that while preclinical data is encouraging, clinical results in actual patients are the true measure of efficacy. Dr. LaRosa and CEO James Frakes explained the decision to cancel the India trial was primarily strategic, driven by unforeseen regulatory slowness in India that could have significantly delayed the overall program and subsequent PMA application, making the focus on Australia the fastest path forward.

    Ask Fintool Equity Research AI

    Marla Marin's questions to AETHLON MEDICAL (AEMD) leadership • Q4 2025

    Question

    Marla Marin of Zacks Investment Research inquired about Aethlon Medical's primary strategic focus, asking if oncology remains the top priority despite new initiatives in long COVID. She also questioned the cost-efficiency of the long COVID collaboration, the expected timeline for data from the Australian oncology trial, and whether nonrecurring executive severance costs have concluded.

    Answer

    CEO & CFO James Frakes confirmed that the company's focus remains "almost entirely on oncology," positioning the long COVID research as a cost-effective, early-stage opportunity. He stated that preliminary data from the first Australian cohort is expected in about three months. Frakes also clarified that the final executive severance payouts are scheduled to conclude by September 2025, and he does not anticipate further similar costs.

    Ask Fintool Equity Research AI

    Marla Marin's questions to AETHLON MEDICAL (AEMD) leadership • Q3 2025

    Question

    Marla Marin asked for more details on the first three patients in the Australian oncology study, questioning why two did not proceed to treatment and how this affects the 9-to-18 patient enrollment target. She also inquired if the new, amended protocol would be used for the India trial and asked about the Australian R&D tax rebate.

    Answer

    Chief Medical Officer Dr. Steven LaRosa clarified that the 9-to-18 patient target refers specifically to Hemopurifier-treated patients, so two new patients will be needed for the cohort. He confirmed the amended protocol will also be submitted for the India trial to improve efficiency. CEO and CFO James Frakes added that the new protocol eliminates a two-month run-in period and confirmed that Australian trial expenses are eligible for a 43% cash rebate, which is filed for annually after the March fiscal year-end.

    Ask Fintool Equity Research AI

    Marla Marin's questions to AETHLON MEDICAL (AEMD) leadership • Q2 2025

    Question

    Marla Marin inquired about the progress of Aethlon's Australian oncology trial, asking if the first two patients represent different tumor types, the company's confidence in securing ethics approval for a third site, and the mechanics of the 43% tax benefit in Australia.

    Answer

    Executive Steven Larosa confirmed the first two patients have two different tumor types representative of those treated with anti-PD-1 therapies. He also expressed high confidence in the third site's approval, noting it's contingent on a minor radiation assessment update. CEO James Frakes explained the Australian financial incentive is a 43% cash payment on all project-related expenses incurred in the country, which is submitted for annually.

    Ask Fintool Equity Research AI

    Marla Marin's questions to LogicMark (LGMK) leadership

    Marla Marin's questions to LogicMark (LGMK) leadership • Q2 2025

    Question

    Marla Marin from Zacks Investment Research inquired about LogicMark's customer mix as it expands into broader safety demographics and asked about the potential impact of government funding cutbacks on its long-term partnership with the VA.

    Answer

    CEO & Director Chia-Lin Simmons explained that the business is still heavily skewed towards the government sector and medical alerts but is expanding into adjacent areas like senior and independent living. Regarding the VA, Simmons stated that while administrative changes are possible, the company has not seen a slowdown in demand for its products for aging veterans and doesn't anticipate one, as the fundamental need persists.

    Ask Fintool Equity Research AI

    Marla Marin's questions to LogicMark (LGMK) leadership • Q3 2024

    Question

    Marla Marin inquired about the market traction for the new Freedom Alert Mini, the strategy for direct-to-consumer sales via Amazon, the potential for licensing the company's growing IP portfolio, and any early customer feedback on the Aster product.

    Answer

    CEO Chia-Lin Simmons attributed the Freedom Alert Mini's success to its differentiated features and active marketing to partners like the Veterans Administration. She noted that while direct-to-consumer efforts on Amazon are promising, it is still early. Simmons confirmed a strategic focus on building a licensable IP portfolio, particularly in applied AI, and mentioned that the company is still gathering feedback to refine the new Aster product.

    Ask Fintool Equity Research AI

    Marla Marin's questions to LogicMark (LGMK) leadership • Q2 2024

    Question

    Marla Marin inquired about the company's strategy for its Direct-to-Consumer (DTC) channel and the growth prospects for its new Aster safety app, which targets a broader demographic beyond elder care.

    Answer

    CEO Chia-Lin Simmons detailed the DTC strategy, emphasizing sales through the company website, app stores, and particularly Amazon, where they are optimizing logistics and product listings. Simmons explained that while the traditional elder care market remains strong, the Aster app opens a significant new Total Addressable Market (TAM) by addressing widespread personal safety concerns and enabling B2B2C partnerships.

    Ask Fintool Equity Research AI

    Marla Marin's questions to LogicMark (LGMK) leadership • Q4 2023

    Question

    Marla Marin of Bluegrass Capital Partners inquired about the market reception for the new Aster software, plans for third-party device integration, and the specifics of the Q4 goodwill impairment charge.

    Answer

    Executive Chia-Lin Simmons addressed the product questions, stating that the Aster app, especially when paired with its Bluetooth button, is receiving positive initial feedback for its unique, user-friendly design that enhances personal safety. Simmons also confirmed that LogicMark is in discussions to integrate third-party services and devices to expand its Caring Platform as a Service (CPaaS) ecosystem, citing potential integrations for medicine reminders and biometric monitoring. CFO Mark Archer explained that the goodwill impairment charge was a non-cash charge related to the original LogicMark acquisition, which predates the current management team, and was necessitated by the company's current market capitalization.

    Ask Fintool Equity Research AI

    Marla Marin's questions to AMERICAN SHARED HOSPITAL SERVICES (AMS) leadership

    Marla Marin's questions to AMERICAN SHARED HOSPITAL SERVICES (AMS) leadership • Q1 2025

    Question

    Marla Marin of Blue Deep Capital inquired about the potential impact of regulatory changes to reimbursement on the company's revenue and asked about the ability to manage fixed cost absorption with the addition of a new center in Rhode Island.

    Answer

    Executive Raymond Stachowiak clarified that the company has minimal exposure to Medicaid, mitigating risks from reimbursement changes, as revenue is primarily driven by private insurers and Medicare. He also explained that the expanding Direct Patient Services segment offers greater control over operations, which will help manage the fixed-cost business model as new centers are added.

    Ask Fintool Equity Research AI

    Marla Marin's questions to AMERICAN SHARED HOSPITAL SERVICES (AMS) leadership • Q4 2024

    Question

    Marla Marin inquired about the potential synergies and economies of scale from American Shared Hospital Services' expanding footprint in Rhode Island, specifically asking about the benefits of the Brown University agreement and the proximity of new facilities to existing ones.

    Answer

    Executive Chairman Raymond Stachowiak confirmed that there will be synergies from their new relationship with Brown University Health. He highlighted that AMS has strong partnerships with the three largest healthcare systems in the small state of Rhode Island: Brown University Health for professional services, and both Care New England and Prospect Charter Care as 20% equity owners in their three radiation therapy centers, which will advance cancer care in the state.

    Ask Fintool Equity Research AI

    Marla Marin's questions to CoreCivic (CXW) leadership

    Marla Marin's questions to CoreCivic (CXW) leadership • Q1 2025

    Question

    Marla Marin of Zacks Investment Research questioned how much room CoreCivic has to negotiate higher per diem rates before losing its cost advantage and asked which other idle facilities are strategically located and attractive to government partners like ICE.

    Answer

    CEO Damon Hininger explained that CoreCivic remains highly cost-competitive compared to city/county rates, federal alternatives, and potential international options. CFO David Garfinkle added that their existing, built-out capacity provides a significant price advantage. Hininger identified idle facilities in Tennessee (near Memphis), Oklahoma (large, centrally located), and Colorado (serving the western U.S.) as the most attractive next options for ICE.

    Ask Fintool Equity Research AI

    Marla Marin's questions to CoreCivic (CXW) leadership • Q4 2024

    Question

    Marla Marin asked about the low-cost initiatives CoreCivic could undertake in advance of a contract award to shorten the start-up time for an idle facility. She also inquired if the South Texas facility would require significant retrofitting to operate under a more standard contract model.

    Answer

    President Patrick Swindle explained that CoreCivic has already formed an internal activation team and is performing pre-activation work, creating project plans, and preparing leadership and training teams to shorten the typical 4-6 month timeline, potentially by 2-3 months in high-priority locations. CEO Damon Hininger stated that any retrofitting for the South Texas facility would be "very modest" as it was only recently deactivated.

    Ask Fintool Equity Research AI

    Marla Marin's questions to CoreCivic (CXW) leadership • Q3 2024

    Question

    Marla Marin inquired about the typical timeline from a Request for Information (RFI) to a Request for Proposal (RFP) for detention capacity and asked if staffing for new contract awards would require new hiring or if personnel were already in the pipeline.

    Answer

    CEO Damon T. Hininger explained that while there is no standard timeline, ICE can move very quickly, citing the 120-day activation of the South Texas facility as an example of their ability to expedite the process when needed. CFO David Garfinkle added that a typical RFI-to-RFP process might take six months but could be accelerated. Regarding staffing, Hininger stated that CoreCivic has a 'playbook' and populated pipelines ready to scale up hiring, with associated costs being part of the start-up expenses for new contracts. Garfinkle clarified they have not hired in advance for idle facilities but could absorb 1,500-2,000 additional people in currently operational facilities.

    Ask Fintool Equity Research AI